Avenzo Therapeutics, Inc.

Privately held: no public share price · United States

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 1/2
CDK2Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 1/2
CDK4Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 1/2
EGFR / HER3 (ERBB3) dualAntibody–drug conjugate
Non-Small Cell Lung Cancer

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
January 2028 (1)
AVZO-021Phase 1/2Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer …
Est. primary completion 2028-01-31 · NCT05867251 · CT.gov ↗
What to watch
August 2028 (1)
AVZO-021 + AVZO-023Phase 1/2HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer
Est. primary completion 2028-08 · NCT06998407 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
AVZO-1418Phase 1/2Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers, Epithelial Tumor, Biliary Tract Cancer (BTC) …
Est. primary completion 2030-06 · NCT07038343 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 June 2026PresentationAVZO-021Updated Phase 1/2 (NCT05867251) data at ASCO 2026: monotherapy median PFS reported across doses in HR+/HER2- breast cancer

Financial reports

No financial reports recorded.